Journal: ACS Applied Materials & Interfaces
Article Title: Development of Au x Cu y Pd z Nanocomposites as Therapeutic Agents: Enhancing Cancer Treatment through Autophagy Modulation and Immune-Associated Effects
doi: 10.1021/acsami.5c20536
Figure Lengend Snippet: In vivo mechanism validation by orthotopic MB49 tumor-bearing mice. (a) Schematic illustration of treatment groups and experiment timelines for the mouse orthotopic bladder cancer model. Ultrasound imaging (b) and the normalized growth curve (c) of the tumor growth for the MB49 tumor-bearing mice received Au 36 Cu 5 Pd 59 micronanoshells and Au 86 Cu 14 nanoshells. The related survival rate and body weight curve are shown in (d,e), respectively. Scale bar = 2 mm in (b). (f) The major organ (heart, lung, liver, kidney, spleen, tumor) H&E staining images of Au 36 Cu 5 Pd 59 micronanoshells, Au 86 Cu 14 nanoshells, and particle-free groups. Scale bar = 100 μm. (g) The biodistribution of Au 36 Cu 5 Pd 59 micronanoshells at different time points (1 h, 1 day, 3 days, and 7 days). N.D. means less than 0.1 ppm. (h) The tumor IHC images of Au 36 Cu 5 Pd 59 micronanoshells, Au 86 Cu 14 nanoshells, and particle-free groups for autophagy, ferroptosis, and immune cell markers. Scale bar = 200 μm.
Article Snippet: T24 and MB49 cells cultured in 6-well dishes (2 × 10 5 per well) subjected to 0.01, 0.025, and 0.05 mM Au 72 Cu 28 or Au 36 Cu 5 Pd 59 NP treatments (w/o CQ and MG-132) for 8 and 16 h were harvested and lysed in lysis buffer (M-PER mammalian protein extraction reagent, Thermo Fisher Scientific, Inc.) for 30 min on ice and then centrifuged at 14,000 rpm for 20 min at 4 °C to remove precipitates.
Techniques: In Vivo, Biomarker Discovery, Imaging, Staining